TY - JOUR
T1 - Gut microbiota and cancer
T2 - How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
AU - Gori, Stefania
AU - Inno, Alessandro
AU - Belluomini, Lorenzo
AU - Bocus, Paolo
AU - Bisoffi, Zeno
AU - Russo, Antonio
AU - Arcaro, Guido
PY - 2019/11
Y1 - 2019/11
N2 - Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.
AB - Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.
KW - 5-Fluorouracil
KW - Cisplatin
KW - Cyclophosphamide
KW - Gemcitabine
KW - Immune checkpoint inhibitors
KW - Irinotecan
KW - Microbiota
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85073270640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073270640&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2019.09.003
DO - 10.1016/j.critrevonc.2019.09.003
M3 - Review article
C2 - 31634731
AN - SCOPUS:85073270640
VL - 143
SP - 139
EP - 147
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -